The efficacy of combined low dose of allopurinol and benzbromarone compared to standard dose of allopurinol in hyperuricemia

Journal of the Medical Association of Thailand

Volumn 87, Issue 9, 2004, Pages 1087-1091

  Akkasilpa, Somchai ^a   Osiri, Manathip ^a   Deesomchok, Utis ^a   Avihingsanon, Yingyos ^a  

^a CHULALONGKORN UNIVERSITY   (Thailand)

Author keywords

Allomaron; Allopurinol; Benzbromarone; Hyperuricemia

Indexed keywords

ALANINE AMINOTRANSFERASE; ALLOPURINOL; ALLOPURINOL PLUS BENZBROMARONE; ASPARTATE AMINOTRANSFERASE; BENZBROMARONE; COLCHICINE; PROBENECID; SULFINPYRAZONE; URIC ACID; URICOSURIC AGENT; XANTHINE OXIDASE INHIBITOR;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DOSE TIME EFFECT RELATION; DRUG EFFICACY; FEMALE; HUMAN; HYPERURICEMIA; LIVER DYSFUNCTION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; PROSPECTIVE STUDY; SIDE EFFECT; STATISTICAL SIGNIFICANCE; URIC ACID BLOOD LEVEL;

ALLOPURINOL; BENZBROMARONE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; GOUT; GOUT SUPPRESSANTS; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TREATMENT OUTCOME; URIC ACID; URICOSURIC AGENTS;

EID: 5544224736     PISSN: 01252208     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Hall AP, Barry PE, Dawber TR, McNamara PM. Epidemiology of gout and hyperuricemia: A long term population study. Am J Med 1967; 42: 27-37.
2. Zolokar J. Serum uric acid in 23923 men and gout in a subsample of 4257 men in France. J Chronic Dis 1972; 25: 305-12.
3. Paulus HE, Coutts A, Calabro JJ, et al. Clinical significance of hyperuricemia in routinely screened hospitalized men. JAMA 1970; 21: 277-81.
4. Saggiani F, Pitati S, Targher G, et al. Serum uric acid and related factors in 500 hospitalized subjects. Metabolism 1966; 45: 1557-61.
5. Agudelo C, Wise C. Crystal-associated arthritis. Clin Geriatr Med 1998; 14: 495-513.
6. Tomita M, Mizuno S, Yamanaka H, et al. Does hyperuricemia affect mortality? a prospective cohort study of japanese male workers. J Epidemiol 2000; 10: 403-9.
7. Day RO, Miners JO, Birkett DJ, et al. Allopurinol dosage selection relationship between dose and plasma oxipurinol and urate concentrations and urinary urate excretion. Br J Clin Pharmacol 1988; 26: 423-8.
8. Rott KT, Agudelo C. Gout. JAMA 2003; 289: 2857-60.
9. Schepers G. Benzbromarone therapy in hyperuricemia; Comparison with allopurinol and probenecid. J Int Med Res 1981; 9: 511-5.
10. Hanvivavadhanakul P, Akkasilpa S, Deesomchok U. Efficacy of benzbromarone compared to allopurinol in loweing serum uric acid level in hyperuricemic patients. J Med Assoc Thai 2002; 85(Suppl 1): S40-7.
11. Perez-Ruiz F, Calabozo M, Pijoan J, Herrero-Beites A, Ruibal A. Effect of urate-loweing therapy on the velocity of size reduction of tophi in chronic gout. Arthritis Rheum 2002; 47: 356-60.
12. Perez-Ruiz F, Alonso-Ruiz A, Calabozo M, Herrero-Beites A, Garcia-Erauskin G, Ruiz-Lucea E. Efficacy of allopurinol and benzbromarone for the control of hyperuricemia. A pathogenic approach to the treament of primary chronic gout. Ann Rheum Dis 1998; 57: 545-9.
13. Colin JN, Farinotti R, Fredji G, et al. Kinetics of allopurinol & oxipurinol after chronic oral administration. Interaction with benzbromarone. Eur J Clin Pharmacol 1986; 31: 53-8.
14. Wallace SL, Singer JZ. Therapy in gout. Rheum Dis Clin North Am 1988; 14: 441-57.
15. Heel RC, Brogden RN, Speight TM, Avery GS. Benzbromarone: A review of its pharmacological properties and therapeutic use in gout and hyperuricemia. Drugs 1977; 14: 349-66.
16. Kelly WN. Pharmacologic approach to the manifestation of urate homeostasis. Nephron 1975; 14: 99-115.
17. Goldfarb E, Smyth CJ. Effects of allopurinol, a xanthine oxidase inhibitors and sulfinpyrazone upon the urinary and serum urate concentration in eight patients with tophaceous gout. Arthritis Rheum 1966; 9: 414-9.
18. Tjandramaga TB. Observation on the disposition of probenecid on patients receiving allopurinol. Pharmacology 1972; 8: 259-72.
19. Weinberger A, Schreiber M, Sperling O, DeVeris A. A comparative evaluation of uricosuric and allopurinol treatment in a series of 183 gouty patients. Intern Rev Rheum 1975; 5: 681-5.
20. Scott JT. Comparison of allopurinol to probenecid. Ann Rheum Dis 1996; 25: 623-6.